Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by fredgoodwinsonon Dec 08, 2020 2:11pm
209 Views
Post# 32059379

13 & 14

13 & 14

Patients 13 & 14 will be our patients 5 & 6 (i.e.optimally dosed - this time twice).

 

They may well already have 30-day data for one of them. Only 37 days` after P.6`s single treatment they were able to pronounce:

 

‘To date the patient has shown no evidence or presence of disease’ This was interpreted as them having confidence at a very early stage (correctly as it turned out) of an enduring complete response.

 

So there may well be highly price sensitive already available from these recent treatments .Whether they feel inclined or able to publish it independently from the results of the second treatments remains to be seen - probably not.

 

Even so and although statistically insignificant for many of us these two will be the acid test for the NMIBC Trial. Some time in June?

 
<< Previous
Bullboard Posts
Next >>